Table 1 Study population characteristics.
From: Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases
HC (n = 26) | AS (n = 52) | PSA (n = 16) | RA (n = 18) | |
|---|---|---|---|---|
age, years (median and range) | 40.1 [26;64] | 41.0 [23;73] | 47.9 [26;71] | 53.6 [22;84] |
male/female, no. | 16/10 | 32/20 | 9/7 | 4/14 |
HLA-B27 positive, % | na | 86.7† | 50.0† | na |
RF positive, % | na | na | na | 75.0‡ |
anti-CCP positive, % | na | na | na | 86.7* |
BASDAI (SD) | na | 4.6 (2.5)+ | na | na |
DAS28 CRP (SD) | na | na | na | 2.7 (1.3)^ |
CRP, mg/L (SD) | na | 18.4(26.9)∞ | 17.1 (27.5)∞ | 7.5 (9.9)∞ |
Treatment | ||||
anti-TNF, no. | na | 11/52 | 1/16 | 0/18 |
DMARD, no. | na | 10/52 | 13/16 | 18/18 |
Steroid, no. | na | 0/52 | 0/16 | 0/18 |
Comorbidities | na | na | na | |
Uveitis, no. | 13/52 | |||
Psoriasis, no. | 4/52 | |||
IBD (UC/CD), no. | 6/52 | |||
